Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Thomson Medical GroupFRA:3H5 +2.94% Debt-to-EBITDA is 13.88 as of Dec. 2025, which is 94% above its 10-year median of 7.14. The stock has 6 warning signs investors should review. Among 478 Healthcare Providers & Services companies, Thomson Medical Group ranks worse than 95.82% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Thomson Medical Group's Debt-to-EBITDA or its related term are showing as below:
FRA:3H5'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.42 Med: 7.14 Max: 19.43
Current: 19.43
During the past 13 years, the highest Debt-to-EBITDA Ratio of Thomson Medical Group was 19.43. The lowest was -5.42. And the median was 7.14.
FRA:3H5's Debt-to-EBITDA is ranked worse than 95.82% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.195
vs FRA:3H5: 19.43
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Thomson Medical Group Debt-to-EBITDA Related Terms
Thomson Medical Group Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Thomson Medical Group's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:3H5 vs HCA, THC, DVA: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Thomson Medical Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thomson Medical Group Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Thomson Medical Group's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Thomson Medical Group's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Thomson Medical Group (FRA:3H5) has a Debt-to-EBITDA of 13.88 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Thomson Medical Group. This is 94% above median its historical median of 7.14. According to the industry distribution chart, Thomson Medical Group ranks #458 out of 478 companies in the Healthcare Providers & Services industry, placing it in the top 95.8%.
Is Thomson Medical Group's Debt-to-EBITDA too high?
Thomson Medical Group's current Debt-to-EBITDA of 13.88 is 94% above median its 10-year median of 7.14. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.20. Thomson Medical Group's value of 13.88 is 532.3% above this industry median. Based on the distribution chart, Thomson Medical Group ranks #458 out of 478 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does Thomson Medical Group's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Thomson Medical Group ranks #458 out of 478 companies for Debt-to-EBITDA. This places Thomson Medical Group in the lower half of its industry. The industry median Debt-to-EBITDA is 2.20. Thomson Medical Group's value of 13.88 is 532.3% above this benchmark. While the company's 10-year median is 7.14 vs. the industry median of 2.20, Thomson Medical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.20, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thomson Medical Group's current Debt-to-EBITDA of 13.88 is 532.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Thomson Medical Group. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thomson Medical Group's current Debt-to-EBITDA is 13.88, which is 94% above median its own 10-year median of 7.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thomson Medical Group stock overvalued right now?
Based on GuruFocus' analysis, Thomson Medical Group (FRA:3H5) is currently considered Possible Value Trap. The stock's GF Value™ is €0.05, compared to a current price of €0.04 — trading 30% below its estimated fair value. The current Debt-to-EBITDA is 13.88, which is 94% above median its 10-year median of 7.14 and 532.3% above the Healthcare Providers & Services industry median of 2.20. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Thomson Medical Group (FRA:3H5), the current Debt-to-EBITDA is 13.88 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Thomson Medical Group Ltd is a provider of healthcare services for women and children. Its segments include Hospital services; Specialised services and Investment holdings. It generates maximum revenue from the Specialised services segment. The specialised services segment includes services provided by fertility clinics, paediatric centres, cancer centre, cardiology centre, Chinese medicine, specialist skin centre and a pre-natal and clinical diagnostic laboratory and project-related services such as managing vaccination centres, COVID-19 Treatment Facilities and Transitional Care Facilities. It also includes a consumer business segment, comprising products and services. Geographically, it derives a majority of its revenue from Singapore.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3H5 has been successfully added to your 
